These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37730124)

  • 21. Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Liu H; Yerevanian A; Westerhoff M; Hastings MH; Guerra JRB; Zhao M; Svensson KJ; Cai B; Soukas AA; Rosenzweig A
    Diabetes; 2024 Feb; 73(2):260-279. PubMed ID: 37934943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project.
    Nabrdalik K; Kwiendacz H; Irlik K; Hendel M; Drożdż K; Wijata AM; Nalepa J; Janota O; Wójcik W; Gumprecht J; Lip GYH
    Cardiovasc Diabetol; 2023 Nov; 22(1):318. PubMed ID: 37985994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic dysfunction-associated steatotic liver disease and the heart.
    Driessen S; Francque SM; Anker SD; Castro Cabezas M; Grobbee DE; Tushuizen ME; Holleboom AG
    Hepatology; 2023 Dec; ():. PubMed ID: 38147315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between Alcohol Consumption and Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Alcohol Flushing Response in Men: The Korea National Health and Nutrition Examination Survey 2019-2021.
    Kang DE; Oh SN
    Nutrients; 2023 Sep; 15(18):. PubMed ID: 37764685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MELD-Na score may underestimate disease severity and risk of death in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
    Yardeni D; Shiloh A; Lipnizkiy I; Nevo-Shor A; Abufreha N; Munteanu D; Novack V; Etzion O
    Sci Rep; 2023 Dec; 13(1):22113. PubMed ID: 38092876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic NLRP3-Derived Hsp70 Binding to TLR4 Mediates MASLD to MASH Progression upon Inhibition of PP2A by Harmful Algal Bloom Toxin Microcystin, a Second Hit.
    Roy S; Saha P; Bose D; Trivedi A; More M; Xiao S; Diehl AM; Chatterjee S
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Shin S; Kim J; Lee JY; Kim J; Oh CM
    J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applying proteomics in metabolic dysfunction-associated steatotic liver disease: From mechanism to biomarkers.
    Zhang X; Li X; Xiong X
    Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102230. PubMed ID: 37931846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targets.
    Liu J; Hu S; Chen L; Daly C; Prada Medina CA; Richardson TG; Traylor M; Dempster NJ; Mbasu R; Monfeuga T; Vujkovic M; Tsao PS; Lynch JA; Voight BF; Chang KM; Million VA; Cobbold JF; Tomlinson JW; van Duijn CM; Howson JMM
    medRxiv; 2023 Nov; ():. PubMed ID: 38076879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.
    Chan WK; Chuah KH; Rajaram RB; Lim LL; Ratnasingam J; Vethakkan SR
    J Obes Metab Syndr; 2023 Sep; 32(3):197-213. PubMed ID: 37700494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between diet soft drink consumption and metabolic dysfunction-associated steatotic liver disease: findings from the NHANES.
    Wu Y; Tan Z; Zhen J; Liu C; Zhang J; Liao F; Dong W
    BMC Public Health; 2023 Nov; 23(1):2286. PubMed ID: 37985986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals.
    Martínez-Domínguez SJ; García-Mateo S; Gargallo-Puyuelo CJ; Gallego-Llera B; Callau P; Mendi C; Arroyo-Villarino MT; Simón-Marco MÁ; Ampuero J; Gomollón F
    Inflamm Bowel Dis; 2024 Aug; 30(8):1274-1283. PubMed ID: 37607330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation.
    Siddiqui MS; Muthiah M; Satapathy SK; Patidar KR; Bhat M; Brandman D; Watt KD; Rinella M
    Hepatology; 2023 Dec; ():. PubMed ID: 38088872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
    Staufer K; Stauber RE
    Biomedicines; 2023 Jul; 11(8):. PubMed ID: 37626604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage.
    Clayton-Chubb D; Kemp WW; Majeed A; Lubel JS; Woods RL; Tran C; Ryan J; Hodge A; Schneider HG; McNeil JJ; Roberts SK
    Liver Int; 2024 Jan; 44(1):39-51. PubMed ID: 37698034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roles of immune dysregulation in MASLD.
    Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H
    Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Mechanisms of Curcumin in the Pathogenesis of Metabolic Dysfunction Associated Steatotic Liver Disease.
    Guariglia M; Saba F; Rosso C; Bugianesi E
    Nutrients; 2023 Dec; 15(24):. PubMed ID: 38140312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease.
    Martínez-Sanz J; Talavera-Rodríguez A; Díaz-Álvarez J; Rosas Cancio-Suárez M; Rodríguez JM; Alba C; Montes ML; Martín-Mateos R; Burgos-Santamaría D; Moreno S; Serrano-Villar S; Sánchez-Conde M
    Front Immunol; 2023; 14():1297378. PubMed ID: 38162648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.